open access

Vol 72, No 3 (2021)
Clinical vignette
Submitted: 2021-02-18
Accepted: 2021-02-23
Early publication date: 2021-04-08
Get Citation

Type 3 autoimmune polyglandular syndrome with multiple genetic alterations in a young male patient with type 1 diabetes mellitus

Abel Decmann1, Judit Tőke1, Éva Csöregh2, Géza Gáspárdy2, Anikó Somogyi2
DOI: 10.5603/EP.a2021.0035
·
Pubmed: 34010447
·
Endokrynol Pol 2021;72(3):286-287.
Affiliations
  1. Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary
  2. Department of Internal Medicine and Haematology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

open access

Vol 72, No 3 (2021)
Clinical Vignette
Submitted: 2021-02-18
Accepted: 2021-02-23
Early publication date: 2021-04-08

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

diabetes mellitus type 1; pernicious anaemia; Hashimoto’s thyroiditis; homocysteine; autoimmune polyglandular syndrome

About this article
Title

Type 3 autoimmune polyglandular syndrome with multiple genetic alterations in a young male patient with type 1 diabetes mellitus

Journal

Endokrynologia Polska

Issue

Vol 72, No 3 (2021)

Article type

Clinical vignette

Pages

286-287

Early publication date

2021-04-08

Page views

747

Article views/downloads

301

DOI

10.5603/EP.a2021.0035

Pubmed

34010447

Bibliographic record

Endokrynol Pol 2021;72(3):286-287.

Keywords

diabetes mellitus type 1
pernicious anaemia
Hashimoto’s thyroiditis
homocysteine
autoimmune polyglandular syndrome

Authors

Abel Decmann
Judit Tőke
Éva Csöregh
Géza Gáspárdy
Anikó Somogyi

References (5)
  1. Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2018; 19 Suppl 27: 7–19.
  2. Morawiec-Szymonik E, Foltyn W, Marek B, et al. Pernicious anaemia and endocrine glands antibodies. Endokrynol Pol. 2019; 70(2): 143–150.
  3. Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol. 2011; 58(10): 1025–1033.
  4. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000; 151(9): 862–877.
  5. Clarke R, Bennett DA, Parish S, et al. MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012; 9(2): e1001177.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl